Method for Reversal of Scleroderma-Associated Fibrotic Signatures Using Single-Cell Transcriptomic Analysis and Kinase Inhibition — USPTO Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification for a computational and pharmacological method for identifying therapeutic candidates for Systemic Sclerosis (SSc) and associated Pulmonary Arterial Hypertension (PAH). The method integrates single-cell RNA-sequencing data from GEO dataset GSE138669 (60,827 cells from scleroderma skin biopsies) using a scVI variational autoencoder to define disease-specific cell clusters, isolates the transcriptional signature of the activated myofibroblast population (Cluster 15) as the primary disease-driving cell type, and queries the LINCS L1000 perturbational database to identify small molecules producing inverse correlation with the disease signature. Human-directed pathway prioritization selects MAPK/ERK and SRC-family kinase inhibitors as primary therapeutic targets. Primary candidates identified: PD-0325901 (MEK1/2 inhibitor, highest composite priority score) and dasatinib (SRC/ABL multi-kinase inhibitor, FDA-approved). Complementary analysis of GEO dataset GSE195452 identifies Epstein-Barr Virus (EBV)-induced immune scarring as the upstream mechanistic trigger of SSc fibrosis, and the Galectin-9 (LGALS9) / TIM-3 (HAVCR2) regulatory axis as a tissue-restricted immune checkpoint and potential stratification biomarker. Human inventorship documented via the Audit of Intent (AOI) five-gate protocol in compliance with USPTO 2024 guidance on AI-assisted inventions. USPTO Provisional Application No. 63/990,695, Confirmation No. 1709, filed February 25, 2026.

Fields of Study & Subjects

Systemic Sclerosis and Related Diseases Pulmonary Hypertension Research and Treatments Dupuytren's Contracture and Treatments

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
23 March 2026
Language
EN